Streamlining Oncology Prior Authorization with Cognizant TriZetto Integration

Klivira optimizes the intricate landscape of oncology prior authorization by seamlessly integrating with your existing EMR and payer connectivity solutions, including Cognizant TriZetto for robust claims and PA submission.

Oncology prior authorization is among the most demanding clinical workflows, characterized by high-cost biologics, frequent regimen changes, and urgent treatment timelines. For health systems utilizing Cognizant TriZetto as a clearinghouse and payer platform, integrating intelligent automation is critical to manage this complexity, reduce administrative burden, and ensure timely patient care.

The Unique Prior Authorization Landscape in Oncology

Oncology care involves a high volume of prior authorization events, spanning from initial diagnosis and staging through complex treatment regimens and ongoing surveillance. These PAs are often triggered by high-cost J-code chemotherapy and biologic infusions, advanced imaging like PET/CT, radiation oncology procedures (IMRT, SBRT), and specialty oral oncolytics, each demanding precise documentation and rapid turnaround.

Key Oncology PA Triggers and Documentation Requirements

**Chemotherapy and Biologic Infusions:** HCPCS J-codes for regimens often require PA per cycle or regimen change, guided by NCCN Clinical Practice Guidelines and NCCN Drugs & Biologics Compendium.
**Advanced Imaging:** PET/CT, advanced MRI, and tumor-specific molecular imaging for staging and surveillance. Documentation often includes clinical rationale and prior imaging results.
**Radiation Oncology:** IMRT, IGRT, SBRT, brachytherapy, and proton-beam therapy CPT ranges. Requires treatment plan approval, prescribed dose, and target volume rationale.
**Genetic and Molecular Testing:** Somatic and germline tumor profiling (NGS panels) for treatment selection, requiring documentation of clinical question and actionability.
**Supportive Care Medications:** Growth factors (G-CSF, ESAs), antiemetics, and bone-targeting agents (denosumab, zoledronic acid), each with distinct PA pathways.

Navigating Payer Connectivity via Cognizant TriZetto for Oncology Workflows

Cognizant TriZetto serves as a critical clearinghouse and payer platform, facilitating the electronic exchange of healthcare transactions, including prior authorizations. For oncology, this means managing the submission of X12 278 requests and receiving responses across a diverse set of payers. Klivira integrates with your EMR to intelligently route PA requests through the appropriate channels, leveraging TriZetto's robust connectivity to streamline the submission process for both medical and pharmacy benefit oncology treatments.

Common Oncology Prior Authorization Denial Vectors

**Off-label Use Without Compendium Support:** Requests for drugs outside NCCN Compendium categories or specific tumor types.
**Step Therapy Requirements:** Payer mandates for failure or contraindication of less-costly alternatives before approval of requested agent.
**Documentation Gaps:** Missing pathology reports, molecular markers (e.g., EGFR, ALK, PD-L1), prior-line treatment response, or performance status (ECOG/Karnofsky).
**Site-of-Service Mismatch:** Discrepancies between requested infusion setting (HOPD vs. home infusion) and payer policy.
**NCD/LCD Non-Coverage:** Denials for Medicare Advantage plans based on Original Medicare's National or Local Coverage Determinations (CMS-0057-F).

Klivira's Intelligent Automation for Oncology and TriZetto Workflows

Klivira's prior authorization automation platform is engineered to address the specific challenges of oncology, enhancing efficiency when working with clearinghouses like Cognizant TriZetto. Our solution features NCCN-compendium-aware policy logic to ensure documentation accuracy, supports regimen-level PA workflows for complex multi-drug therapies, and intelligently routes medical-benefit vs. pharmacy-benefit PAs. This integration reduces manual touchpoints, accelerates PA approvals, and helps oncology practices maintain focus on patient care amidst urgent treatment timelines.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for oncology drugs when integrating with TriZetto?

Klivira intelligently identifies whether an oncology drug falls under the medical or pharmacy benefit. For medical benefit drugs (e.g., J-coded infusions), requests are routed via X12 278 through clearinghouses like Cognizant TriZetto. For pharmacy benefit oral oncolytics, Klivira routes to the appropriate PBM and ePA partners, ensuring each PA follows the correct channel without manual intervention.

What specific oncology PA triggers does Klivira automate?

Klivira automates PA processes for high-volume oncology triggers including J-code chemotherapy and biologic infusions, advanced imaging (PET/CT, MRI), radiation oncology procedures (IMRT, SBRT), genetic and molecular testing (NGS panels), and supportive care medications. Our system tracks these concurrent PA events throughout a patient's treatment course.

How does Klivira support NCCN guideline adherence in oncology prior authorization?

Klivira incorporates NCCN-compendium-aware policy logic into its automation platform. This capability prompts for required documentation based on specific oncology regimens, tumor types, and molecular markers, ensuring that submissions align with widely accepted medical necessity criteria from sources like the NCCN Clinical Practice Guidelines and NCCN Drugs & Biologics Compendium.

Can Klivira help reduce denials related to documentation gaps in oncology prior authorization?

Yes, a core strength of Klivira is its ability to identify and surface documentation requirements at the point of order entry. By prompting for essential information such as pathology reports, molecular markers, prior-line treatment responses, and performance status (e.g., ECOG score), Klivira significantly reduces the incidence of denials due to incomplete or missing clinical data.

How does Klivira streamline peer-to-peer reviews for oncology cases?

Klivira streamlines the peer-to-peer review process by flagging clinical-necessity denials and facilitating scheduling integrations for oncologist-payer discussions. This ensures that oncologists can efficiently engage in these critical reviews, providing necessary clinical context to overturn denials and minimize treatment delays for patients.